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Objective: To measure the extent to which health-related quality of life (HRQoL) in people living with HIV is
associated with duration of antiretroviral therapy (ART) after controlling for sociodemographic, clinical, and
other therapy-related factors.
Design: Cross-sectional analysis.
Methods: A gender-stratified random sample of 421 participants aged 1864 years was selected from the
patients on ART at a health facility in Kenya. Three hundred and ninety two patients participated in the
study, representing a 93% response rate. Data on general physical and mental health functioning status were
collected using the SF-36 health survey questionnaire. Hierarchical logistic regression analysis was used to
predict the SF-36 summary scores.
Results: In regression analyses, the duration of ARTwas negatively associated with HRQoL (odds ratio (OR):
0.6, 95% confidence interval (CI): 0.450.92) after controlling for sociodemographic, clinical, and other
therapy-related factors. Patients with chronic diseases or clinical symptoms of acute illness had significantly
worse HRQoL (OR: 0.5, 95% CI: 0.300.79 and OR: 0.3, 95% CI: 0.160.59, respectively). Therapy
interruptions, adverse drug reactions, and World Health Organization stage at initiation of therapy were not
associated with HRQoL.
Conclusion: Patients on ART for a relatively longer duration reported poorer HRQoL at the study facility
independent of the effect of other therapy-related, clinical, and sociodemographic factors. Program managers
and clinicians in the Kenyan health system may need to refocus attention on this subgroup to avert ‘loss to
treatment’ that may have negative repercussions on the substantial gains made against the HIV scourge.
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W
hile the HIV epidemic remains a major global
public health concern, and more so in devel-
oping countries, considerable gains have been
made in stemming its economic and social toll on
communities (1). Antiretroviral therapy (ART) regimens
have been a key component to much of these gains as
they have contributed to increased longevity and reversal
of disease progression (2, 3). However, they are not
without challenges as they involve a strict treatment
protocol, including adherence to the therapies; the need
to handle the adverse drug reactions associated with the
potent medicines; and the development of strategies to
deal with the psychosocial and other life events asso-
ciated with living with HIV (4). Although much has been
studied on how these and other factors interact to affect
patients’ perception of their general health status, more
needs to be presented on how these vary over the course
of treatment and their joint temporal impact on patients’
self-assessed general health.
Health-related quality of life (HRQoL) is a multi-
dimensional psychometric construct that is distinct from
the concept of ‘quality of life’ in that it focuses on those
aspects of the human experience and a person’s assess-
ment of the same that are amenable to health interven-
tions (5). It derives summary measures from people’s
subjective evaluations of their physical, mental, and emo-
tional health and functioning. Several self-administered
generic and disease-specific instruments have been devel-
oped and used in measuring HRQoL in people living
with HIV (PLHIV) (6, 7). Most studies assessing HRQoL
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(page number not for citation purpose)in PLHIV have been limited largely to the assessment of
clinical, psychosocial, and/or sociodemographic HRQoL
correlates, with few studies performed in resource-poor
settings (8).
Of those that have assessed the variation of HRQoL
in PLHIV with time, findings have been mixed. On
one hand, in a longitudinal study assessing factors asso-
ciated with HRQoL, Jelsma et al. (9) found that HRQoL
improved in a South African cohort over a 12-month
follow-up, although the sample consisted largely of mem-
bers with similar pretreatment clinical health status. On
the other hand, Carrieri et al. (10), in a heterogeneous
sample with respect to pretherapy health status, reported
general improvements in HRQoL over a similar period in
patients with a poorer baseline clinical status but not in
those with a moderate-to-normal baseline clinical status.
A plausible explanation provided was that those patients
initiating therapy when moderately immunocompromised
were in the long run more likely to regard the cons of HIV
treatment higher than its benefits. Comparable findings
have been made in other similarly designed studies (3, 11)
as well as qualitative studies (12), where HRQoL has been
shown to have differential improvement over time with
respect to some other clinical or biodemographic factor(s).
Few studies have considered to what extent the HRQoL
changes in PLHIV can be independently explained by
duration on therapy as the primary predictor or by taking
longitudinal measurements past the 12-month mark. This
is in light of evidence that biochemical changes attribu-
table to HIVand AIDS, even with treatment, span awider
temporal window (13) and may, through biophysical
manifestations, influence patients’ evaluation of their
health condition.
The aim of the this study was therefore to investigate
to what extent duration on ART in PLHIV predicts
patients’ self-perceived health status independent of their
current and pretreatment clinical health status as well as
other well-known therapy-related and sociodemographic
factors associated with HRQoL. If duration of ART is
associated with changes in HRQoL, then a good level of
understanding of the underlying mechanisms may aid
health system and HIV program managers to supple-
ment objective clinical status measurements with self-
assessed general health in ensuring an optimal health
outcome environment among patients at different stages
of treatment.
Methods
Design
Thecross-sectionalstudy wasconducted betweenFebruary
and April 2013 at Nyeri Provincial General Hospital
(Nyeri PGH), Nyeri County, Kenya. Nyeri County is
located in the central highlands of Kenya, about 150 km
north of the capital Nairobi. Nyeri PGH is the main
referral hospital in the region, with the catchment area
extending to at least four other neighboring counties. As
a regional referral hospital, it serves both curative and
rehabilitative functions in addition to preventive services
to a population of about 700,000. HIV prevalence in Nyeri
County is estimated at 4.4% compared to the national
average of 6.2% (14).
The study was conducted between February and April
2013. The study’s sampling frame was obtained from the
list of patients actively taking ART at the hospital as of
January 2013, that is, all patients who were enrolled in the
ART program in January 2013 or earlier and were still
active on treatment. Patients were eligible for inclusion if
they were aged between 18 and 64, had been on highly
active ART (HAART) for at least 1 month, and had
a clinic appointment within the study period. Conse-
quently, from a total population of 1,693 patients on
HAART, 1,189 met the inclusion criteria. Since HIV
prevalence is biased on gender (1) (and the sampling
frame comprised 69.0% females), a final sample of 421
patients was aggregated from a proportionate simple
random sample from each of the two gender-stratified
groups of the sampling frame. Sample size was deter-
mined from the World Health Organization’s (WHO)
Practical Manual for Sample Size Determination in
Health Studies (15), where a minimum sample size of
380 would have been adequate to estimate an odds ratio
(OR) of at least 1.5 at the 5% significance level.
Data collection and ethical considerations
Data were collected using paper questionnaires adminis-
tered in privacy to the patients. Written approval for the
study was sought and obtained from the hospital man-
agement prior to commencement. All participants were
informed of the study’s purpose prior to participation,
and informed verbal consent was subsequently obtained.
They were informed that the services they receive at the
hospital would continue as usual whether or not they
elected to participate. For those unable to complete the
questionnaire for physical, literacy, or other reasons, the
questions were read to them as written and in their
preferred language (66.1% preferred the Kiswahili to the
English version).
Outcome variables
The 36-Item Short-Form Health Survey (SF-36) (16)
instrument was used to collect information on patients’
HRQoL profile. The SF-36 scores health on eight
subscales, ranging from physical functioning to mental
health, and two summary measures: a physical compo-
nent score (PCS) and mental component score (MCS) (7,
16). For categorical analyses, PCS and MCS were
dichotomized at their respective medians, yielding ordinal
binary ‘high’ and ‘low’ variables. To simplify interpreta-
tion, athirdvariable was generated as a Cartesian product
of the PCS and MCS, and was dichotomized into ‘high’
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the aggregated PCS and MCS variable was also classified
as ‘high’ in both the PCS and MCS variables.
Independent variables
The study’s primary explanatory variable (duration of
ART) and control variables were obtained from an
addendum to the SF-36, clinical, and pharmacy records.
The electronic clinical and pharmacy records were im-
ported and collated into a software application with a
relational database management system at the backend.
The variables were classified into three broad categories:
Sociodemographic factors
Information on age and gender was obtained from the
pharmacy records, whereas information about the parti-
cipants’ education, income, marital status, religion, and
occupation was captured through the addendum to the
SF-36. Table 1 summarizes the variable levels used in
analysis.
Clinical factors
Patients’ pretreatment clinical status was assessed using
the WHO HIV stage at therapy initiation obtained from
clinical records. Information on the patients’ current
health was obtainedfromquestions about theirexperience
of acute and HIV-related constitutional symptoms in the
4 weeks preceding the interview as well as comorbidi-
ties. Checklists from prior studies assessing constitutional
symptoms (17) and chronic illness burden in PLHIV (18)
were used together with disease patterns data in the study
area to generate responses for the questions on current
chronic illnesses and symptoms of acute illness in the
month prior to the study.
Therapy-related factors
Pharmacy and clinical records were used to obtain
information on medication adherence, therapy interrup-
tions, and clinic appointments. Medication adherence
was weighted with the extent to which patients made
clinic appointments on time. The algorithm is summar-
ized in Annex I. The broader definition of adherence
incorporates a behavioral aspect of HIV treatment that is
consistent with the more comprehensive WHO definition
of adherence (19) and builds on conceptual frameworks
incorporating retention in care as a factor in defining
engagement in HIV care (20).
Statistical analyses
Sample characteristics were assessed using measures
of central tendency and dispersion. Further analysis of
dependence involved the Pearson chi-square test of
independence and the OR.
In order to study the effect of duration on ART on
HRQoL and how this effect improved the ability to
predict membership in the levels of the binary HRQoL
outcome variables after controlling for the potential
confounders, a three-step hierarchical binomial regres-
sion analysis approach was used. In the initial step, all
sociodemographic factors were entered into the regres-
sion equation, followed by the clinical factors. Clinical
factors were included in the second step. In the final step,
all of the therapy-related factors, including duration
on ART, were added, and the changes in the predictive
abilities of the models at each step were assessed using the
likelihood ratio test and model accuracy. An additional
step, where the duration variable was added separately
from the other therapy-related factors, was used to
establish the overall importance of the variable indepen-
dent of the other theoretically related variables.
A two-tailed p-value of less than 0.05 was considered
statistically significant for all hypothesis tests. Data were
analyzed using Stata/SE 12.0 and IBM† SPSS† Statistics.
Results
Sample characteristics
A total of 392 patients participated in the study, repre-
senting a 93% response rate. Table 1 summarizes the
patient characteristics and their associations with the
primary independent variable. ORs (not shown) were
computed for each variable in the table, with the last level
being the reference category. The sample was predomi-
nantly female (68.9%), and the overall mean age was 41.4
(SD8.3) years. The final gender distribution was
consistent with the gender distribution in the sampling
frame (69.0% female) and target population (69.8%
female). Except for religion and income, other socio-
demographic factors were not significantly associated
with duration on ART, indicating that duration was
independent of the participants’ age, gender, education
level, marital status, and occupation. Table 1 also shows
that the participants more likely to report a preexisting
chronic condition were also those who had been longer
on ART (OR: 2.6, 95% CI [confidence interval]: 1.64
4.07). Adherence was associated with duration on ART
(with adherenceB80% as the reference; 80%5adherence
B95% OR: 3.9, 95% CI: 2.296.56; and adherence]95%
OR: 12.8, 95% CI: 5.9927.47).
The median time on ART for the sample was 4.5 years
(interquartile range: 2.66.5 years), and this was used
to dichotomize the duration on ART variable for the
regression analyses.
Predicting HRQoL in PLHIV
Mental component scores
In the baseline model (Table 2), age (OR: 0.7, 95% CI:
0.550.97), gender (OR: 2.1, 95% CI: 1.313.44), religion
(OR: 1.8, 95% CI: 1.352.48), and occupation (OR: 1.5,
95% CI: 1.162.05) were significant predictors of MCS
in the absence of clinical and therapy-related factors.
In step 2, age ceased to be a significant predictor, whereas
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two were fully and partially statistically mediated by one
or more clinical factors, respectively. Addition of therapy-
related factors failed to improve the model (LR x
28.2,
not significant (NS)), and none of the therapy-related
factors were significant.
Table 1. Participants’ characteristics and contrast between those on ART for less than 4.5
a years versus those on ART for 4.5
years or more
Duration on ART
n (%
b) ]4.5 years B4.5 years x
2 p value
c
Total (n) 392 (100) 195 197
Sociodemographic factors
Gender Male 122 (31.1) 67 55 NS
Female 270 176 128
Age (years) ]45 127 (32.4) 70 57 NS
]36 to B45 148 (37.8) 75 73
18 to B36 117 50 67
Education College or above 68 (17.3) 35 33 NS
Secondary school 132 (33.7) 65 67
Primary or below 192 95 97
Income (KES
d) ]10,000 79 (20.1) 41 38 B0.05
]5,000 to B10,000 119 (30.4) 47 72
B5,000 194 107 87
Marital status Currently married 166 (42.3) 77 89 NS
Previously married 163 (41.6) 84 79
Never married 63 34 29
Religion Protestant 196 (50.0) 88 108 B0.05
Catholic 138 (35.2) 68 70
Other 58 39 19
Occupation Paid employment 197 (50.3) 91 106 NS
Homemaker 119 (30.4) 64 55
None 76 40 36
Clinical factors
Clinical symptoms ]1 symptom 209 (53.3) 109 100 NS
No symptoms 183 86 87
Chronic illnesses ]1 chronic illness 115 (29.3) 76 39 B0.05
No chronic illness 277 119 158
WHO stage at start Stage 4 63 (16.1) 54 9 B0.05
Stage 3 111 (28.3) 58 53
Stage 2 121 (30.9) 54 67
Stage 1 97 29 68
Therapy-related factors
Adherence
e Optimal 57 (14.5) 19 38 B0.05
Fair 258 (65.8) 141 117
Poor 77 35 42
ADRs ]1 ADR 185 (47.2) 122 63 B0.05
No ADR 207 73 134
Therapy interruptions ]1 interruption 253 (64.5) 156 97 B0.05
No interruption 139 39 100
ART: antiretroviral therapy; NS: not significant; WHO: World Health Organization; ADRs: Adverse drug reactions.
aMedian duration on ART (4.5 years) used as cutoff for short versus long.
bProportion displayed for each variable’s levels but one.
cPearson’s chi-square test of independence.
dKenyan shillings (USD 1.00:KES 84.85 as of 4 July 2013).
eRefers to the multidimensional adherence explained in Annex I.
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The three-step hierarchical regression analysis yielded
incrementally preferred models from the baseline to the
final model, both with respect to deviance (from LR
x
248.4, pB0.05, to LR x
215.5, pB0.05) and to
model accuracy (from 63.0 to 70.2%) (Table 3). In the
baseline model, all sociodemographic factors except
gender and income were significant PCS predictors. In
step 2, clinical factors fully explained the effect of age.
In the final model, duration on ART was a significant
predictor (OR: 0.7, 95%: CI 0.470.93), with a distinct
downward-sloping effect size gradient (duration 35
Table 2. Hierarchical binomial logistic regression analysis of the MCS of the SF-36 against sociodemographic, clinical, and
therapy-related factors showing odds ratios and 95% CI (n392)
Independent variable
a Step 1
b Step 2
c Step 3
d
Age (years) 0.7 (0.550.97) 0.8 (0.611.10) 0.9 (0.641.19)
]45 0.5 (0.300.98) 0.7 (0.361.27) 0.8 (0.411.51)
]36 to B45 0.6 (0.320.97) 0.6 (0.361.14) 0.7 (0.391.28)
Sex 2.1 (1.313.44) 1.8 (1.093.00) 1.9 (1.123.13)
Education 1.0 (0.731.33) 0.9 (0.671.25) 0.9 (0.691.30)
College or above 0.8 (0.441.61) 0.7 (0.381.47) 0.8 (0.391.54)
High school 1.2 (0.731.94) 1.1 (0.661.82) 1.1 (0.661.85)
Monthly income (KES) 1.1 (0.791.40) 1.1 (0.781.42) 1.0 (0.741.38)
]10,000 1.0 (0.551.81) 1.0 (0.541.89) 0.9 (0.481.82)
]5,00010,000 1.5 (0.932.55) 1.5 (0.872.51) 1.4 (0.782.33)
Marital status 1.1 (0.811.46) 1.1 (0.811.49) 1.0 (0.761.42)
Currently married 1.1 (0.561.99) 1.1 (0.552.08) 1.0 (0.511.98)
Previously married 0.8 (0.451.59) 0.9 (0.451.64) 0.8 (0.431.64)
Religion 1.8 (1.352.48) 1.9 (1.362.55) 1.8 (1.332.52)
Protestant 3.5 (1.826.92) 3.7 (1.857.38) 3.6 (1.777.23)
Catholic 2.2 (1.114.33) 2.3 (1.154.73) 2.3 (1.144.79)
Occupation 1.5 (1.162.05) 1.5 (1.101.98) 1.5 (1.112.02)
Paid employment 2.5 (1.364.58) 2.3 (1.234.33) 2.4 (1.244.45)
Homemaker 1.5 (0.772.93) 1.6 (0.773.12) 1.5 (0.753.07)
Clinical symptoms 0.5 (0.320.78) 0.5 (0.320.78)
Chronic illnesses 0.4 (0.250.68) 0.4 (0.260.73)
WHO stage at start 1.0 (0.831.28) 1.1 (0.861.36)
Stage 4 1.0 (0.512.13) 1.2 (0.532.54)
Stage 3 1.1 (0.612.10) 1.2 (0.612.23)
Stage 2 0.9 (0.501.67) 0.9 (0.491.70)
Adherence 0.8 (0.551.19)
Optimal 0.6 (0.281.44)
Fair 0.9 (0.531.72)
Adverse drug reactions 0.7 (0.431.15)
Therapy-interruptions 1.5 (0.872.47)
Duration on ART (years) 0.8 (0.561.08)
]5 0.6 (0.301.19)
]3.5 to B5 0.7 (0.351.42)
Likelihood ratio test x
2]41.7, pB0.05
e x
2]26.7, pB0.05
f x
2]8.2, NS
f
Accuracy (%) 63.5 68.1 69.6
Note: Both sigma-coded and overparameterized models used. MCS: mental component score; ART: antiretroviral therapy; CI: confidence
interval; KES: Kenyan shillings; NS: not significant; WHO: World Health Organization.
aReference category for variable indicated in Table 1.
bRegression step with sociodemographic factors only.
cRegression step with sociodemographic and clinical factors only.
dFinal model with all of the variables.
eComparison with the constant-only model (null deviance).
fComparison with the previous step’s model.
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years, OR: 0.5, 95% CI: 0.240.99). The presence of
clinical symptoms and chronic illnesses was predictive of
poorer PCS (OR: 0.5, 95% CI: 0.340.87; and OR: 0.3,
95% CI: 0.190.56, respectively).
HRQoL scores (aggregated PCS and MCS)
Table 3 shows that the predictive utility of the models,
from the baseline to the final, improved in both deviance
(from LR x
239.1, pB0.05, to LR x211.5, pB0.05)
and accuracy (from 69.6 to 73.2%). Results from steps 1
Table 3. Hierarchical binomial logistic regression analysis of the PCS of SF-36 against sociodemographic, clinical, and therapy-
related factors showing odds ratios and 95% CI (n392)
Independent variable
a Step 1
b Step 2
c Step 3
d
Age (years) 0.7 (0.510.90) 0.8 (0.591.07) 0.9 (0.651.21)
]45 0.5 (0.280.92) 0.7 (0.361.29) 0.8 (0.421.62)
]36 to B45 0.6 (0.320.98) 0.7 (0.381.22) 0.8 (0.421.41)
Sex 1.5 (0.932.43) 1.2 (0.752.07) 1.4 (0.822.32)
Education 1.4 (1.071.97) 1.4 (1.021.94) 1.5 (1.082.10)
College or above 1.9 (1.003.72) 1.9 (0.923.77) 2.2 (1.074.55)
High school 1.6 (0.962.52) 1.5 (0.882.42) 1.7 (1.002.89)
Monthly income (KES) 0.9 (0.691.23) 0.9 (0.681.26) 0.8 (0.601.14)
]10,000 0.8 (0.431.42) 0.8 (0.411.50) 0.6 (0.321.21)
]5,00010,000 1.3 (0.792.19) 1.3 (0.762.25) 1.1 (0.631.94)
Marital status 0.7 (0.510.95) 0.7 (0.490.93) 0.6 (0.450.88)
Currently married 0.4 (0.220.82) 0.4 (0.190.78) 0.3 (1.160.68)
Previously married 0.5 (0.270.98) 0.5 (0.250.97) 0.5 (0.220.92)
Religion 1.9 (0.362.52) 1.9 (1.362.60) 1.8 (1.312.55)
Protestant 3.3 (1.696.43) 3.4 (1.676.74) 3.1 (1.496.34)
Catholic 1.7 (0.853.33) 1.7 (0.823.40) 1.4 (0.693.02)
Occupation 1.5 (0.152.06) 1.5 (1.081.98) 1.5 (1.102.03)
Paid employment 2.3 (1.224.16) 2.0 (1.063.87) 2.1 (1.094.10)
Homemaker 1.2 (0.612.34) 1.2 (0.592.47) 1.3 (0.612.66)
Clinical symptoms 0.6 (0.350.88) 0.5 (0.340.87)
Chronic illnesses 0.3 (1.170.48) 0.3 (0.190.56)
WHO stage at start 1.0 (0.821.28) 1.2 (0.931.53)
Stage 4 1.1 (0.512.23) 1.8 (0.794.13)
Stage 3 1.1 (0.602.08) 1.4 (0.702.68)
Stage 2 0.9 (0.481.64) 1.0 (0.511.83)
Adherence 0.7 (0.461.03)
Optimal 0.4 (1.191.05)
Fair 0.4 (0.240.82)
Adverse drug reactions 0.8 (0.511.38)
Therapy-interruptions 0.8 (0.471.35)
Duration on ART (years) 0.7 (0.470.93)
]5 0.5 (0.240.99)
]3.5 to B5 0.8 (0.411.65)
Likelihood ratio test x
2]48.4, pB0.05
e x
2]35.2, pB0.05
f x
2]15.5, pB0.05
f
Accuracy (%) 63.0 68.4 70.2
Note: Both sigma-coded and overparameterized models used. PCS: physical component score; ART: antiretroviral therapy; CI:
confidence interval; KES: Kenyan shillings; WHO: World Health Organization.
aReference category for variable indicated in Table 1.
bRegression step with sociodemographic factors only.
cRegression step with sociodemographic and clinical factors only.
dFinal model with all of the variables.
eComparison with the constant-only model.
fComparison with the previous step’s model.
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16% reduction in gender’s effect size in step 2. In the
final step, duration on ART was a significant predictor
of HRQoL score, as was adherence (OR: 0.6, 95%
CI: 0.450.92; and OR: 0.6, 95% CI: 0.410.96, respec-
tively). Similar to the PCS regression, a negative dose-
dependent-like effect size gradient was discerned for the
association between duration and HRQoL scores. The
effect of age was fully statistically mediated in the final
model, suggesting that the variance in classification of
overall health scores explained by age was indistinguish-
able from that explained by the therapy-related factors.
Sensitivity analyses
In order to test whether duration on ART significantly
changed the models’ predictive ability independently, the
variable was removed from the cluster of therapy-related
variables and added in a fourth step separately. Results
(not shown) indicated that duration remained significant
in the fourth model, and it performed better than the
step 3 model (without duration; HRQoL scores step 4:
LR x
26.0, pB0.05; PCS model step 4: LR x
25.7,
pB0.05; and MCS model step 4: LR x
22.3, NS).
The multidimensional adherence variable was disag-
gregated, and the individual medication adherence and
visit adherence variables were entered separately as part
of the therapy-related factors into the final step. The two
did not significantly alter other variables’ CIs or model
fit, and they were not significant predictors in any of the
three final models. It was thus inferred that they did not
contribute much to the models on their own relative to
the combined variable.
Discussion
The main finding in this observational cross-sectional
study is that duration on ART was found to predict
poorer overall self-perceived health status after control-
ling for sociodemographic, clinical, and other therapy-
related factors. From the analysis of sociodemographic
factors, better HRQoL was associated with male gender,
Christian faith, higher education, and paid employment,
although the exact mechanism through which they
(particularly gender and age) impact health status may
be partially statistically explained by aspects of therapy
and current clinical status (Tables 2, 3, and 4).
Duration on ART
Although this study assessed patients on ART over a
relatively wider time span than most prior work (9, 10,
21), the results are largely consistent with findings from
similarly designed studies. Tran (22) present results that
show a decline or stagnation in mean subscale scores
after 4 years on treatment in five of the six HRQoL
health domains measured, although the instrument used
was different, thereby limiting direct comparisons. The
mechanism through which duration on ART influences
HRQoL has not been extensively studied and is therefore
unclear.
Based on the notion of treatment fatigue in HIV
treatment (23, 24), however, we posit that, with time,
HRQoL becomes sensitive to cumulative adverse drug
effects and personal and professional adjustments to one’s
life. This may in part explain the short-term HRQoL gains
commonly observed in the 12-month longitudinal studies.
This proposition is strengthened by studies (25) that
suggest that in Kenya, labor participation is significantly
lower in PLHIV than in the general population. A related
postulation is that, as the clinical condition of PLHIV
asymptotically approaches normalcy, the engagement
between patients and healthcare providers may wane.
On the health system’s part, this may happen when the
health system’s capacity is not matched with increasing
treatment coverage, thereby shifting clinical focus to the
newly enrolled patients or those in need of immediate
attention. Complacency on the patients’ part contributes
to poorer medication adherence, dissatisfaction, and
noncompliance with clinicopharmaceutical instructions
(26), all of which may translate to conceivably poorer
HRQoL in the long run.
Pre- and posttreatment clinical status
Participants who had concurrent chronic comorbidities
and/or had experienced clinical symptoms of an acute
illness in the previous month were more likely to rate
their health states significantly lower than those who had
been free of the same, irrespective of duration on ARTor
other therapy-related factors. This would appear reason-
able, since such physiological aberrations typically man-
ifest physically, emotionally, and socially, hence affecting
the perception of one’s general health (5, 27).
In the analysis, duration on ART was associated with
both chronic comorbidities and pretreatment WHO HIV
stage (Table 1). This may imply a greater disease burden
(both clinical and self-assessed) among those on ART for
longer periods. This presents a policy opportunity to
mitigate possibly temporally worsening health status in
PLHIV. It is with this in mind that investments in routine
screening of patients for constitutional clinical symptoms
and other health problems, irrespective of treatment stage
orwithgreaterfocusonthoseonARTforlongerduration,
should be made so that psychosocial and other complica-
tions associated with low HRQoL may be averted.
The paradox of adherence
In this study, a multidimensional measure of adherence
was used (Annex I), justified by an a priori understanding
of adherence in HIV and the post-hoc sensitivity analy-
ses. Adherence was negatively associated with HRQoL,
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association strengthened away from the null with increas-
ing adherence. While most studies have found high
adherence to be a significant predictor of better HRQoL
(28, 29), others have found no association (30). Though
this may be design related, since this study captured both
phenomena simultaneously thereby resulting in the ob-
servation that better adherers were also at a poorer
health state and vice versa, two possibilities arise. Firstly,
because of poorer pretreatment or deteriorating in-
treatment health status, patients may be more motivated
(both internally and externally) to increase their adher-
ence to medication and instructions (multidimensional
adherence). Conversely, as a patient’s health approaches
Table 4. Hierarchical binomial logistic regression analysis of the aggregated MCS and PCS of SF-36 against sociodemographic,
clinical, and therapy-related factors showing odds ratios and 95% CI (n392)
Independent variable
a Step 1
b Step 2
c Step 3
d
Age (years) 0.6 (0.460.84) 0.7 (0.520.98) 0.8 (0.541.05)
]45 0.4 (0.220.78) 0.5 (0.271.03) 0.6 (0.291.18)
]36 to B45 0.4 (0.250.78) 0.5 (0.260.89) 0.5 (0.270.96)
Sex 2.1 (1.273.44) 1.7 (1.032.94) 1.9 (1.123.28)
Education 1.1 (0.771.44) 1.0 (0.701.36) 1.0 (0.721.43)
College or above 1.0 (0.481.91) 0.8 (0.361.60) 0.8 (0.381.74)
High school 1.3 (0.782.17) 1.2 (0.722.10) 1.3 (0.732.21)
Monthly income (KES) 0.9 (0.641.78) 0.9 (0.621.19) 0.8 (0.561.11)
]10,000 0.7 (0.341.26) 0.7 (0.331.36) 0.6 (0.271.19)
]5,00010,000 1.4 (0.832.38) 1.3 (0.752.30) 1.2 (0.652.10)
Marital status 0.8 (0.601.13) 0.8 (0.581.13) 0.8 (0.531.06)
Currently married 0.6 (0.301.16) 0.6 (0.281.17) 0.5 (0.241.04)
Previously married 0.7 (0.341.30) 0.7 (0.301.32) 0.6 (0.291.24)
Religion 1.8 (1.282.53) 1.8 (1.272.57) 1.8 (1.222.51)
Protestant 3.3 (1.517.15) 3.3 (1.467.26) 3.0 (1.306.72)
Catholic 1.8 (0.834.11) 1.9 (0.824.29) 1.8 (0.754.10)
Occupation 1.7 (1.212.26) 1.6 (1.152.21) 1.6 (1.152.24)
Paid employment 2.7 (1.375.29) 2.6 (1.285.37) 2.7 (1.295.53)
Homemaker 1.3 (0.622.88) 1.4 (0.603.10) 1.4 (0.593.11)
Clinical symptoms 0.5 (0.300.78) 0.5 (0.300.79)
Chronic illnesses 0.3 (0.140.52) 0.3 (0.160.59)
WHO stage at start 1.1 (0.861.36) 1.2 (0.911.52)
Stage 4 1.2 (0.532.61) 1.5 (0.633.62)
Stage 3 1.7 (0.883.28) 1.8 (0.873.56)
Stage 2 1.2 (0.622.33) 1.2 (0.582.31)
Adherence 0.6 (0.410.96)
Optimal 0.4 (0.140.90)
Fair 0.6 (0.341.20)
Adverse drug reactions 1.0 (0.581.70)
Therapy-interruptions 1.4 (0.832.53)
Duration on ART (years) 0.6 (0.450.92)
]5 0.4 (0.210.93)
]3.5 to B5 0.8 (0.371.55)
Likelihood ratio test x
2]39.1, pB0.05
e x
2]32.3, pB0.05
f x
2]11.5, pB0.05
f
Accuracy (%) 69.6 72.7 73.2
Note: Both sigma-coded and overparameterized models used. MCS: mental component score; PCS: physical component score; ART:
antiretroviral therapy; CI: confidence interval; KES: Kenyan shillings; WHO: World Health Organization.
aReference category for variable indicated in Table 1.
bRegression step with sociodemographic factors only.
cRegression step with sociodemographic and clinical factors only.
dFinal model with all of the variables.
eLikelihood ratio test for comparison with the constant-only model.
fComparison with the previous step’s model.
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treatment, they may relax their compliance to medication
and other instructions (26).
Limitations
This being a cross-sectional study, causal relationships
cannot be conclusively determined. Nonetheless, cross-
sectional findings prompt hypotheses justifying further
investigations  a case in point here being the puzzle of
adherence. Though the study sought to control for known
potential confounders, omissions are expected and ac-
knowledged  the most prominent being psychosocial
factors such as stigma, social support networks, depres-
sion, disclosure, and occupation-related health. We cannot
rule out, based on current literature (31, 32), their possi-
bly independent impacts on HRQoL in PLHIV, and
further research into the interplay between such factors
and those used in this study should yield greater under-
standing of the issue at hand.
In addition, since participant selection was partly
based on clinic attendance, those with appointments
outside the study period may have been missed. Post-
hoc cross-tabulation showed no significant differences
between the two groups with respect to gender and age,
but those not selected were more likely to have been on
ART for longer. This is expected as they usually have
widely spaced clinic appointments.
Conclusion
Patients’ assessment of their well-being during HIV treat-
ment was negatively associated with their duration on
treatment irrespective of sociodemographic, clinical, and
other therapy-related variables. This may have impli-
cations in the design and implementation of effective
interventions to improve the uptake and retention of
patients in HIV treatment programs that take atreatment-
stage-targeted approach. In light of the strong negative
association between constitutional symptoms and chro-
nic comorbidities with both treatment duration and
HRQoL, HIV care programs may benefit from strategies
that strengthen the patientprovider relationship with a
particular focus on those on treatment for a relatively
longer duration. Finally, further research into the role
of a wider definition of adherence in HIV research is
recommended.
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Medication adherence was calculated from manual pill count data using the formula:
Ad m f ¼
P X
x¼1
Pd d m f   PCd m f
Rf   days d; d   X ðÞ
where Admf is the adherence computed for the m
th’s participant’s f
th medicine dispensed on the d
th visit; Rf is the f
th
medicine’s dosing information (number of pills per day); PCdmf is the pill count for the f
th medicine presented by the m
th
participant on their d
th visit; X is the number of visits before the d
th visit for which adherence is quantiﬁable; the
summation of Pd xmf for all X is the total number of pills dispensed to the participant for the X visits; and days is a
function computing the difference (in days) between the d
th visit and X visits before that. The numerator is therefore the
actual number of pills consumed during the period d X, and the denominator is the total number of pills expected to be
consumed during the same period. Note that this is a specialization of the widely used Medication Possession Ratio
(MPR) that takes into account within-course therapy regimen changes and deferred pill counts. The participants’
cumulative medication adherence was then computed as the arithmetic mean for all medicines and for all of the visits. For
categorical analysis, the medication adherence variable was transformed into a trinomial variable taking one of the
following values: ‘optimal’ (medication adherence ]0.95), ‘moderate’ (0.95  medication adherence]0.80), and ‘low’
(medication adherenceB0.80).
Clinic appointment compliance was obtained as the number of visits on time (give or take 5 days) divided by the total
number of visits. For categorical analyses, the variable was transformed into a trinomial variable taking one of the
following values: ‘optimal’ (appointment compliance ]0.90), ‘moderate’ (0.75  appointment compliance]0.90), and
‘low’ (appointment compliance B0.80).
To create the multidimensional adherence variable, medication adherence and appointment compliance were com-
bined with the AND and OR Boolean logical operators to produce three levels as follows: ‘optimal’ (medication
adherence ]0.90 AND appointment compliance ]0.80), ‘fair’ (medication adherence ]0.85 AND appointment
compliance B0.80) OR (appointment compliance ]0.75 AND medication adherence B0.90), and ‘low’ (medication
adherence B0.85 AND appointment compliance B0.75).
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